ReviewJournal of hematopathology2025
IgG4 plasma cells in hematopathology: beyond IgG4-related disease.
Review in Journal of hematopathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
IgG4 plasma cells are well-known in the context of IgG4-related disease (IgG4-RD). Meanwhile, their role in other disorders remains enigmatic. In hematopathology practice, the presence of these cells can be non-specific in reactive lymphadenopathy, requiring clinicopathological correlation to exclude IgG4-RD. A high density of IgG4 plasma cells may help distinguish progressive transformation of germinal centers from early nodular lymphocyte-predominant Hodgkin lymphoma. IgG4 plasma cells are also present in a subset of classic Hodgkin lymphomas, particularly the nodular sclerosis subtype. Despite their morphological similarities, Rosai-Dorfman disease and IgG4-RD appear to be distinct entities. Idiopathic multicentric Castleman disease and IgG4-RD can be histologically indistinguishable, which necessitates clinical and laboratory differentiation. Marginal zone lymphoma and, rarely, myeloma can express IgG4, with some cases of marginal zone lymphoma having concurrent IgG4-RD. This review provides a comprehensive analysis of IgG4 plasma cells in hematopathology and discusses their diagnostic significance and associated challenges.
Indexed as
Identifiers
41261290What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.